Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

05. März 2014 08:30 ET | Quelle: Zogenix

Zogenix Reports Granting of Inducement Awards

SAN DIEGO, March 5, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related conditions and central...
27. Februar 2014 16:30 ET | Quelle: Zogenix

Zogenix Announces Conference Call and Webcast to Present Fourth Quarter and Full Year 2013 Financial Results

SAN DIEGO, Feb. 27, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related conditions and central...
13. Februar 2014 08:30 ET | Quelle: Zogenix

Data From Zohydro(TM) ER (hydrocodone bitartrate) Phase 3 Clinical Trial Published in Pain Medicine Demonstrates Its Benefit as a Therapeutic Option for the Management of Pain Severe Enough to Require Daily, Around-the-Clock, Long-Term Opioid Treatment and for Which Alternative Treatment Options Are Inadequate

SAN DIEGO, Feb. 13, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related conditions and central...
12. Februar 2014 13:59 ET | Quelle: Zogenix

Zogenix Establishes External Safe-Use Board

SAN DIEGO, Feb. 12, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system...
11. Februar 2014 08:30 ET | Quelle: Zogenix

Zogenix Provides Update on Zohydro(TM) ER (hydrocodone bitartrate) Launch Readiness Plans

SAN DIEGO, Feb. 11, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related conditions and central...
04. Februar 2014 08:00 ET | Quelle: Zogenix

Zogenix to Present at Leerink Swann 2014 Global Healthcare Conference

SAN DIEGO, Feb. 4, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system disorders and...
04. Februar 2014 07:30 ET | Quelle: Zogenix

Zogenix Reports Granting of Inducement Awards

SAN DIEGO, Feb. 4, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system disorders and...
13. Januar 2014 08:30 ET | Quelle: Zogenix

Zogenix Announces Preliminary Fourth Quarter 2013 Gross Product Sales

SAN DIEGO, Jan. 13, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system disorders and...
09. Januar 2014 08:30 ET | Quelle: Zogenix

Zogenix and Mallinckrodt Agree to End Co-Promotion for SUMAVEL(R) DosePro(R) Effective January 31, 2014

SAN DIEGO, Jan. 9, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system disorders and...
07. Januar 2014 07:30 ET | Quelle: Zogenix

Zogenix Reports Granting of Inducement Awards

SAN DIEGO, Jan. 7, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of central nervous system disorders and...

Vorherige Seite

Nächste Seite